Erlotinib for the treatment of brain metastases in non-small cell lung cancer.
about
Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC).Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model.Best Practices in Treatment Selection for Patients With Advanced NSCLC.
P2860
Erlotinib for the treatment of brain metastases in non-small cell lung cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Erlotinib for the treatment of brain metastases in non-small cell lung cancer.
@en
type
label
Erlotinib for the treatment of brain metastases in non-small cell lung cancer.
@en
prefLabel
Erlotinib for the treatment of brain metastases in non-small cell lung cancer.
@en
P2860
P1476
Erlotinib for the treatment of brain metastases in non-small cell lung cancer.
@en
P2093
H Ian Robins
Jeffrey V Brower
P2860
P304
P356
10.1517/14656566.2016.1165206
P407
P577
2016-03-11T00:00:00Z